Engineering Biopharmaceuticals - An overall increasing proportion of future product approvals will be engineered in some way, either directly or indirectly. - BioPharm International

ADVERTISEMENT

Engineering Biopharmaceuticals
An overall increasing proportion of future product approvals will be engineered in some way, either directly or indirectly.


BioPharm International
Volume 20, Issue 11

6. Li, H., Sethuraman, N., Stadheim, T., Zha, D., Prinz, B. et al. Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat. biotechnol. 2006;24:210–215.

7. Jefferis, R. Glycosylation of recombinant antibody therapeutics. Biotechnol. Progress, 2005;21:11–16.

8. Satoh, M., Iida, S. and Shitara, K. Non-fucosylated therapeutic antibodies as next generation therapeutic antibodies. Exp. Op. Biol. Ther. 2006;6:1161–1173.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

New Tax Rules May Deter Future Pharma M&A
October 1, 2014
NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
Author Guidelines
Source: BioPharm International,
Click here